Efficacy of Onon^® (pranlukast hydrate) for the Improvement of Quality of Life in Patients with Allergic Rhinitis

Abstract

The aim of this study was to evaluate the effects of novel leukotriene antagonist, pranlukast hydrate on improvement of quality of life (QOL) as well as reduction of clinical symptoms in patients with allergic rhinitis.
Fifty patients with perennial and/or seasonal allergic rhinitis were administered 450mg pranlukast hydrate daily for at least 4 weeks. The severity of clinical symptoms and QOL were assessed before and after treatment.
After a 4-week period of treatment, the QOL score significantly improved from 2.1±1.5 to 1.2±1.7 (P<0.0001). In addition, the treatment itself did not affect the QOL of the patients. The severity of symptoms was also significantly reduced (P<0.001). The improvement rates were 66.0% (sneezing), 72.0% (rhinorrea), and 82.0% (nasal obstruction).
In conclusion, pranlukast hydrate improves QOL and reduces symptoms in patients with allergic rhinitis.